Slides
Page 1
Third Quarter 2026 Earnings Call N o v e m b e r 4 , 2 0 2 6 ©2026 Myriad Genetics, Inc.
Page 2
©2026 Myriad Genetics, Inc. Some of the information presented here today contains projections or other forward-looking statements regarding future events or the future financial performance of the Company. FORWARD-LOOKING STATEMENTS AND DISCLAIMERS These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or other forward-looking statements. The Company is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. All third-party marks—® and —are the property of their respective owners. Certain market and industry data has been obtained from third-party sources, which the Company believes are reliable, but the Company has not independently verified the information provided by third-party sources. Unless otherwise noted, market growth rates used in this presentation are estimates based on Company and third-party industry research. NON-GAAP FINANCIAL MEASURES In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. Definitions of the non-GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial results are provided in the Appendix to this presentation. The Company does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the Company's control, or cannot be reasonably predicted at the time of this presentation. Such adjustments include, but are not limited to, strategic realignment, costs related to amortization of intangibles from acquisitions, impairment and related charges, depreciation, equity compensation, tax benefits, and other adjustments. For example, stock-based compensation may fluctuate based on the timing of employee stock transactions and unpredictable fluctuations in the Company's stock price. Any associated estimate of these items and their impact on GAAP performance could vary materially. Forward-looking statements and Non-GAAP financial measures 2 2
Page 3
©2026 Myriad Genetics, Inc. 3 Progress Sam Raha PRESIDENT AND CHIEF EXECUTIVE OFFICER
Page 4
©2026 Myriad Genetics, Inc. Q3‘26 revenue of $202.7M reflects YOY volume changes in: • Cancer Care Continuum: 4% • Mental Health: 3% • Prenatal Health: (11)% YOY changes in average revenue per test of: • Cancer Care Continuum: (3)% • Mental Health: (1)% • Prenatal Health: (1)% Third quarter 2026 performance and takeaways 4 Q3'26 revenue benefits from CCC mix & avg revenue per test Sale of Prenatal business to unlock significant value Announced sale of Prenatal business to Labcorp (10/20) • $210M + inventory, all-cash • Expected to be accretive to revenue growth and profitability • Target close by early 2027 67 .9% gross margins in Q3‘26; 130 basis points higher than Q2'26 $(5.3M) adj EBITDA* and $(0.11) adj EPS* in Q3’26 vs. $(16.9M) adj EBITDA and $(0.25) adj EPS in Q2’26 Solid liquidity position; Access to ~$182M at end of Q3’26 Q3'26 profitability improves from Q2'26 *GAAP to non-GAAP reconciliations for Q3‘26 can be found in the Appendix. Raising mid-point of 2026 revenue guidance to reflect positive Q3'26 progress and current outlook
Page 5
©2026 Myriad Genetics, Inc. Prenatal Health: Unlocking potential value through announced divestiture MYRIAD PRENATAL HEALTH BUSINESS* Deal rationale and expected benefits * Last Twelve Months as of September 30, 2026. Tests Reported (K): ~600 Revenue ($M): $165 Gross Margin: ~40% Maximizes benefits for patients, clinicians, employees and shareholders Improves Myriad’s liquidity, accretive to revenue growth/profitability Enables increased focus on the Cancer Care Continuum market opportunity 1 2 3 5
Page 6
©2026 Myriad Genetics, Inc. 6 Third Quarter 2026 Business Update
Page 7
©2026 Myriad Genetics, Inc. Continuing Hereditary Cancer Test volume growth; Progressing MRD C A N C E R C A R E C O N T I N U U M Third quarter 2026 and recent highlights • Another record high volume quarter for unaffected HCT in last three years • Continued expansion of hereditary cancer testing guidelines • Precise MRD early access testing continues; await reimbursement coverage (MolDX on-track); positive user feedback • In October 2026, Precise MRD CRC data from MONSTAR3 study presented at European Society of Medical Oncology (ESMO) 7 Operational results: $124M Q3‘26 revenue ~98K Q3‘26 test volume Key performance indicators: (1)% Revenue growth1 6% Volume growth1 Hereditary Cancer 1: Q3‘26 Growth YOY 7
Page 8
©2026 Myriad Genetics, Inc. Maintaining leadership with disciplined level of investment and focus M E N T A L H E A L T H 8 Operational results: $40M Q3‘26 revenue ~141K Q3‘26 test volume Key performance indicators: 3% Volume growth1 GeneSight 8 2% Revenue growth1 1: Q3‘26 Growth YOY Third quarter 2026 and recent highlights • Q3’26 GeneSight revenue increased 2% YOY, reflecting a (1)% YOY change in average revenue per test • 40K+ clinicians ordered GeneSight in Q3’26 • Maintaining focus on expanding coverage and go-to-market strategies
Page 9
©2026 Myriad Genetics, Inc. Announced Prenatal Health divestiture: positive for stakeholders P R E N A T A L H E A L T H 9 Prenatal Operational results: $39M Q3‘26 revenue ~138K Q3‘26 test volume 9 Third quarter 2026 and recent highlights • October 20 announced definitive agreement to sell Prenatal Health test business to Labcorp; target close by early 2027 Key business indicators: (12)% Revenue growth1 (11)% Volume growth1 1: Q3‘26 Growth YOY SEE PRESS RELEASE > SEE PRESS RELEASE >
Page 10
©2026 Myriad Genetics, Inc. On-track with key 2026 product publications, submissions and launches Precise MRDHCT • Launched MyRisk Disease Specific Panels; H1‘26 • Increase sample volume growth rate Prostate Cancer • Launched Prolaris + AI test; Q2’26 • Prolaris meta-analysis publication published; July’26 Reported out on FirstGene CONNECTOR study; H1‘26 Commercial launch of FirstGene; July'26 Prenatal Health 10 • Focus on increasing sample volume growth • Expect to add new strategic partnerships as part of growth plan Cancer Care Continuum Initiated commercial testing for select customers; March‘26 MolDX submission for Breast; July'26 Breast publication; MONITOR study published; Q2’26 MolDx submissions for Renal and CRC; H1’27E CRC data publication, MONSTAR3 study; H2’26E
Page 11
©2026 Myriad Genetics, Inc. 11 Financial Update Ben Wheeler CHIEF FINANCIAL OFFICER
Page 12
©2026 Myriad Genetics, Inc. 12 Third quarter 2026 performance Demonstrating progress with multiple initiatives, including revenue cycle management 12 Q3'26 revenue benefits from mix, average test revenue Average revenue per test improved in Q3’26 YOY Positive demand in CCC continues Sale of Prenatal Health business expected to enhance financial profile Ascend initiative-related actions A Look at Myriad Post Sale • Positioned for higher revenue growth and profitability • Focused on Cancer Care Continuum • Simplified operations
Page 13
©2026 Myriad Genetics, Inc. Recent initiatives contribute to improving Q3’26 average revenue per test Comprehensive action plan RCM improvements Team investments -20% -15% -10% -5% 0% $800 $950 $1,100 $1,250 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Hereditary Cancer Test (HCT) Average revenue per test Optimizing workflows to accelerate cash collections and improve predictability Building on past investments in team capabilities and tools to increase precision in claim processing Ongoing third party engagement Advancing reimbursement stability through payer engagement, LBM collaboration, and policy advocacy Average revenue per test YOY Change Key takeaways: • Q3’26 average revenue per HCT declined 6% YOY but improved 9% compared to Q2’26 reflecting traction with recent initiatives • $1,000 - $1,200 range of average revenue per HCT test (Q3’25 – Q3’26) • Prior-period collection adjustments were immaterial in Q3’26 and Q3’25, but reduced Q2’26 revenue by $11 million 9% 13 Change in average revenue per test in Q3’26 over Q2’26
Page 14
©2026 Myriad Genetics, Inc. 14 Continued strong gross profit and healthy liquidity position 1 GAAP to non-GAAP reconciliations can be found in the Appendix 2 Consists of $107 million of cash and cash equivalents and availability of additional $75 million under term loan facility Additional highlights: Sale of Prenatal Health business expected to add ~$200M cash Generated adj operating cash flow1 of $4M; adj free cash flow1 of $2M in Q3’26 Generated approximately $138M Gross Profit in Q3‘26 Adj EBITDA1 Generated a loss of $5M in Q3‘26 Liquidity position2 Access to ~$182M As of September 30, 2026
Page 15
©2026 Myriad Genetics, Inc. Prenatal Health divestiture expected to be a catalyst for unlocking value 15 • $210M + inventory all cash deal; 1.3x revenue* • Deal includes all related tests, test inventory, multiple CA-based facilities and human capital • Expect to close by early 2027; Until then, Prenatal Health business will continue to operate as part of Myriad Genetics (included in 2026 financial guidance) Transaction details Potential use of proceeds • Debt reduction • Growth investments • General corporate purposes Prenatal Health generated revenue of $165M*; gross margins of ~40%* P&L impact and guidance considerations *Trailing twelve months as of September 30, 2026 revenue growth: (YOY) gross margins: 100+ basis points 500+ basis points Potential Benefits (first 12-months post close): 15
Page 16
©2026 Myriad Genetics, Inc. Raising mid-point of full year 2026 revenue guidance range 16 All figures in millions, except percentages Assumes currency rates as of November 4, 2026. *The company does not forecast GAAP gross margin, because it cannot predict certain elements that are included in reported GAAP results. See the statement on Non-GAAP Financial Measures at the beginning of this presentation and the Appendix to this presentation for more information about the use of non-GAAP financial measures. CCC + Mental Health Prenatal Health $620M – $630M ~$160M $780 - $790M UPDATED 2026 REVENUE GUIDANCE Previous $770 - $790M Guidance reflects positive CCC and Mental Health current business trends partially offset by Prenatal Health divestiture dynamics Adjusted gross margin* unchanged at 66% - 67%
Page 17
©2026 Myriad Genetics, Inc. 17 Closing Comments Sam Raha PRESIDENT & CHIEF EXECUTIVE OFFICER
Page 18
©2026 Myriad Genetics, Inc. 18 Taking important actions to better position Myriad to drive accelerated profitable growth Divest Prenatal Health business Mitigate payer friction Increase org efficiency, productivity, and scalability STRATEGIC ACTIONS Financial profile Predictability Focus on the cancer care continuum STRENGTHEN
Page 19
©2026 Myriad Genetics, Inc. 19 Q&A
Page 20
©2026 Myriad Genetics, Inc. Appendix 20
Page 21
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Gross Margin 21 (unaudited data in millions) Three months ended September 30, Nine months ended September 30, 2026 2025 2026 2025 Adjusted Gross Margin Gross Profit $ 137.7 $ 143.8 $ 402.3 $ 429.8 Acquisition - amortization of intangible assets(1) — — 0.1 0.6 Equity compensation(2) 0.2 0.3 0.9 0.9 Strategic realignment(3) 0.4 — 0.4 — Other adjustments(4) — — — 0.3 Adjusted Gross Profit $ 138.3 $ 144.1 $ 403.7 $ 431.6 Adjusted Gross Margin 68.2 % 70.1 % 68.0 % 70.2 % (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees. (3) Costs related to strategic realignment of the company including severance and consulting fees. (4) Other one-time non-recurring adjustments. 21
Page 22
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Operating Expenses 22 (unaudited data in millions) 22 Three months ended September 30, Nine months ended September 30, 2026 2025 2026 2025 Adjusted Operating Expenses Operating Expenses $ 177.6 $ 167.1 $ 511.8 $ 811.3 Acquisition - amortization of intangible assets(1) (6.5) (6.5) (19.3) (23.4) Goodwill and long-lived asset impairment(2) — — (5.4) (316.7) Equity compensation(3) (9.0) (11.9) (22.0) (31.5) Real estate optimization(4) — — — (5.2) Strategic realignment(5) (12.2) (8.3) (16.2) (10.1) Other adjustments(6) — (0.4) — — Adjusted Operating Expenses $ 149.9 $ 140.0 $ 448.9 $ 424.4
Page 23
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Operating Expenses (Cont.) 23 (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Expense related to goodwill and long -lived asset impairment. For the nine months ended September 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting uni ts and asset groups. (3) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors. (4) Costs related to real estate initiatives. For the nine months ended September 30, 2025, consists of additional rent as a resu lt of the build -out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our then existing laborat ories in those locations and testing and set-up costs for equipment in our new facilities. (5) Costs related to strategic realignment of the company including severance and consulting fees. (6) Other one-time non-recurring adjustments. 23
Page 24
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Net Income (Loss) 24 (unaudited data in millions, except per share amounts) 24 Three months ended September 30, Nine months ended September 30, 2026 2025 2026 2025 Adjusted Net Income (Loss)(1) Net Loss $ (43.9) $ (27.4) $ (121.2) $ (358.0) Acquisition - amortization of intangible assets(2) 6.5 6.5 19.4 24.0 Goodwill and long-lived asset impairment(3) — — 5.4 316.7 Equity compensation(4) 9.2 12.2 22.9 32.4 Real estate optimization(5) — — — 5.2 Strategic realignment(6) 12.6 8.3 16.6 10.1 Other adjustments(7) — 0.4 — 0.4 Uncertain tax benefit(8) — — — (29.0) Tax adjustments(9) 4.9 0.2 14.6 0.1 Adjusted Net Income (Loss) $ (10.7) $ 0.2 $ (42.3) $ 1.9 Weighted average shares outstanding: Diluted 95.7 93.8 94.7 93.2 Adjusted Income (Loss) Per Share Diluted $ (0.11) $ — $ (0.45) $ 0.02
Page 25
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025– Adjusted Net Income (Loss) (Cont.) 25 25 (1) To determine Adjusted Income (Loss) Per Share. (2) Represents recurring amortization charges resulting from the acquisition of intangible assets. (3) Expense related to goodwill and long -lived asset impairment. For the nine months ended September 30, 2026 , consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting units and asset groups. (4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors. (5) Costs related to real estate initiatives. For the nine months ended September 30, 2025 , consists of additional rent as a result of the build -out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our then existing laborat ories in those locations and testing and set-up costs for equipment in our new facilities. (6) Costs related to strategic realignment of the company including severance and consulting fees. (7) Other one-time non-recurring adjustments. (8) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended September 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, which upon conclusion of the review were remeasured or released. (9) Tax expense or benefit due to non-GAAP adjustments, differences between stock compensation recorded for book purposes as compared to the allowable tax deductions, and valuation allowance recognized against federal and state deferred tax assets in the United Stat es. As of September 30, 2026, a valuation allowance of $129.1 million was not recognized for non -GAAP purposes given our historical and forecasted positive earnings performance. As of September 30, 2025, a valuation allowance of $104.8 million was not recognized for non -GAAP purposes given the company's historical and forecasted positive earnings performance.
Page 26
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted EBITDA 26 (unaudited data in millions) Three months ended September 30, Nine months ended September 30, 2026 2025 2026 2025 Adjusted EBITDA Net Loss $ (43.9) $ (27.4) $ (121.2) $ (358.0) Acquisition - amortization of intangible assets(1) 6.5 6.5 19.4 24.0 Depreciation expense(2) 4.9 4.8 14.4 14.8 Goodwill and long-lived asset impairment(3) — — 5.4 316.7 Equity compensation(4) 9.2 12.2 22.9 32.4 Real estate optimization(5) — — — 5.2 Strategic realignment(6) 12.6 8.3 16.6 10.1 Interest expense, net of interest income(7) 3.5 3.3 10.6 5.1 Other adjustments(8) 1.6 1.4 4.3 2.5 Uncertain tax benefits(9) — — — (29.0) Income tax expense(10) 0.3 1.2 0.9 0.8 Adjusted EBITDA $ (5.3) $ 10.3 $ (26.7) $ 24.6 26
Page 27
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted EBITDA (Cont.) 27 27 (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Consists of depreciation expense recognized during the period. (3) Expense related to goodwill and long -lived asset impairment. For the nine months ended September 30, 2026, consists of $5.4 million of impairment expense associated with our Women's Health reporting unit and certain intangible assets. For the nine months ended September 30, 2025, consists of $316.7 million of impairment expense associated with our Mental Health and Women's Health reporting uni ts and asset groups. (4) Consists of the non-cash equity-based compensation provided to Myriad Genetics employees and directors. (5) Costs related to real estate initiatives. For the nine months ended September 30, 2025, consists of additional rent as a resu lt of the build -out of our new laboratories in Salt Lake City, Utah and South San Francisco, California, while maintaining our then existing laborat ories in those locations and testing and set-up costs for equipment in our new facilities. (6) Costs related to strategic realignment of the company including severance and consulting fees. (7) Derived from interest expense and interest income from the Condensed Consolidated Statements of Operations. (8) Other one -time non -recurring expenses. For purposes of adjusted EBITDA, this includes Other adjustments described in the Adjusted Net Income (Loss) table above as well as the amounts reported as Other income (expense) in the Condensed Consolidated Statement o f Operations. (9) Consists of the release of unrecognized tax benefits and the recognition of valuation allowances for the nine months ended Se ptember 30, 2025. The unrecognized tax benefits released were primarily related to tax years under Joint Committee on Taxation review, wh ich upon conclusion of the review were remeasured or released. (10) Derived from Income tax expense (benefit) from the Condensed Consolidated Statement of Operations, net of the adjustment for unrecognized tax benefits described in Note 9 above.
Page 28
©2026 Myriad Genetics, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures for the Three and Nine Months Ended September 30, 2026 and 2025 – Adjusted Free Cash Flow 28 (unaudited data in millions) 28 Three months ended September 30, Nine months ended September 30, 2026 2025 2026 2025 Adjusted Operating and Free Cash Flow Net Cash Provided by (Used in) Operating Activities $ (6.5) $ 21.1 $ (30.5) $ (8.8) Real estate optimization(1) — 1.2 — 8.7 Strategic realignment(2) 10.2 2.3 13.1 4.1 Other adjustments(3) — 0.2 — 0.2 Adjusted Operating Cash Flow $ 3.7 $ 24.8 $ (17.4) $ 4.2 Capital expenditures(4) (1.8) (2.8) (9.3) (10.9) Capitalization of internal-use software costs(4) (0.3) (3.4) (2.5) (10.5) Adjusted Free Cash Flow $ 1.6 $ 18.6 $ (29.2) $ (17.2) (1) The cash flow effect of real estate optimizations, excluding non -cash items such as accelerated depreciation. (2) Strategic realignment includes the cash paid for severance and consulting fees. (3) The cash flow effect of other one -time non-recurring expenses. (4) Derived from the Condensed Consolidated Statements of Cash Flows.